P/E at 34.94 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount to Industry Average

The P/E ratio of Sun Pharmaceutical Industries Ltd at 34.94 represents a modest discount of approximately 6% relative to the sector average of 37.19. This suggests that the stock is not trading at a significant premium despite its large-cap stature and strong historical returns. The industry’s elevated P/E reflects generally optimistic earnings expectations, yet Sun Pharma appears to be valued more conservatively. This valuation gap may indicate market caution or a recalibration of growth prospects within the company’s earnings trajectory — previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating? The P/E differential invites investors to consider whether the stock’s earnings quality or risk profile justifies this relative discount.

Performance Across Timeframes: Strong Long-Term Gains, Mixed Recent Momentum

Examining the performance data reveals a compelling divergence between short-term and long-term returns. Over the past year, Sun Pharma has delivered a robust 16.40% gain, significantly outperforming the Sensex’s 9.87% loss during the same period. This outperformance extends further back, with three-year and five-year returns of 59.76% and 128.17% respectively, dwarfing the Sensex’s 10.03% and 21.91% gains. However, the recent three-month return of -1.11% contrasts with the longer-term trend, albeit still outperforming the Sensex’s -5.60% decline. The one-month return of -3.56% also reflects a short-term correction within an otherwise positive medium-term context.

This pattern suggests that while the stock has demonstrated resilience and growth over extended periods, recent market dynamics or company-specific factors have introduced some volatility. The 0.64% gain on the latest trading day, outperforming the sector by 0.62%, hints at a potential stabilisation or renewed interest — is this a genuine recovery or a relief rally that will fade at the 50 DMA? Investors may wish to weigh these short-term fluctuations against the backdrop of sustained long-term appreciation.

Moving Average Configuration: Above 200 DMA but Below Shorter-Term Averages

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a mixed moving average (MA) configuration. The stock price currently sits above its 200-day moving average, a long-term bullish indicator signalling that the broader trend remains positive. However, it trades below the 5-day, 20-day, 50-day, and 100-day moving averages, which suggests recent weakness or consolidation phases within the shorter-term timeframes. This pattern often reflects a recovery attempt within a larger correction or a pause before a potential trend continuation.

Such a configuration can be interpreted as a technical tug-of-war, where short-term momentum is subdued but the long-term trend remains intact. The 0.64% gain on the latest trading day may be an early sign of upward momentum attempting to break through these shorter-term resistance levels — is this a recovery or a dead-cat bounce? The moving average setup thus provides a nuanced view of the stock’s current technical health.

Sector Context: Mixed Results Amidst Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a varied set of results recently, with 28 stocks having declared their earnings. Of these, 13 reported positive outcomes, 11 remained flat, and 4 posted negative results. This distribution indicates a sector experiencing moderate growth with pockets of stagnation and weakness. Within this environment, Sun Pharma’s performance stands out for its relative stability and consistent long-term gains.

Given the sector’s mixed earnings landscape, the company’s ability to maintain a P/E ratio close to the industry average while delivering superior returns over multiple years is noteworthy. This balance between valuation and performance may reflect prudent management and a diversified product portfolio that cushions against sector volatility — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 67.0. The rating was updated on 3 September 2026, reflecting a reassessment of the company’s fundamentals and market conditions. While the current rating is not disclosed, the data-driven evaluation considers valuation metrics, performance trends, and technical indicators to provide a comprehensive view of the stock’s standing.

The reassessment aligns with the observed valuation-performance tension and the mixed moving average signals. The stock’s ability to outperform the Sensex over multiple timeframes while trading at a slight valuation discount suggests a balanced risk-reward profile. However, the recent short-term weakness and technical resistance levels may have prompted a more cautious stance — what is the current rating for Sun Pharmaceutical Industries Ltd?

Conclusion: A Complex Picture of Valuation and Momentum

The data on Sun Pharmaceutical Industries Ltd paints a multifaceted picture. The stock trades at a P/E ratio slightly below the industry average, suggesting a modest valuation discount despite strong long-term returns. Performance over one, three, and five years has been impressive relative to the Sensex, though recent months have seen some softness. The moving average configuration indicates a stock above its long-term trend line but facing short-term resistance, highlighting a potential inflection point.

Within a sector showing mixed earnings results, Sun Pharma remains a significant player with a large market capitalisation of ₹4,44,296.85 crores. The reassessment of its rating from Buy to Hold reflects these nuanced factors, balancing valuation, performance, and technical signals. Investors analysing this stock must consider whether the recent momentum shifts represent a temporary pause or a more sustained change in trend — should investors hold, buy more, or reconsider their position?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →